Natural immunity enhances the activity of a DR5 agonistic antibody and carboplatin in the treatment of ovarian cancer

Molecular Cancer Therapeutics

Volumn 9, Issue 4, 2010, Pages 1007-1018

  El Gazzar, Ahmed ^a   Perco, Paul ^d   Eckelhart, Eva ^b   Anees, Mariam ^a   Sexl, Veronika ^b   Mayer, Bernd ^d   Liu, Yanxin ^e   Mikulits, Wolfgang ^c   Horvat, Reinhard ^a   Pangerl, Thomas ^a   Zheng, Dexian ^e   Krainer, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Institute of Pharmacology   (Czech Republic)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF VIENNA   (Austria)

^e INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AD5 10; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; LAPATINIB; MONOCLONAL ANTIBODY; PACLITAXEL; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MOUSE; NATURAL KILLER CELL; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION;

EID: 77950790831     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0933     Document Type: Article

References (43)

1. 1. Guppy AE, Nathan PD, Rustin GJ. Epithelial ovarian cancer: a review of current management. Clin Oncol (R Coll Radiol) 2005; 17: 399-411. (Pubitemid 41136134)
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 20073B57:43-66.
3. 3. Wong AS, Auersperg N. Ovarian surface epithelium: family history and early events in ovarian cancer. Reprod Biol Endocrinol 2003;1:70. (Pubitemid 39130455)
4. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407: 770-776
5. 5. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006;25:4798-4811 (Pubitemid 44187627)
6. 6. Ashkenazi A. Targeting death and decoy receptors of the tumournecrosis factor superfamlly. Nat Rev Cancer 2002;2:420-430 (Pubitemid 37328939)
7. 7. Horak P, Pils D, Kaider A, et al. Perturbation of the tumor necrosis factor-related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5. Clin Cancer Res 2005;11:8585-8591 (Pubitemid 43005904)
8. 8. Lamhamedi-Cherradi SE, Zheng SJ, Maguschak KA, Peschon J, Chen YH. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice. Nat Immunol 2003;4:255-260 (Pubitemid 36322135)
9. 9. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis In TNFrelated apoptosis-inducing ligand-deficient mice. J Immunol 2002; 168:1356-1361 (Pubitemid 34094506)
10. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008;8: 782-798
11. 11. Guo Y, Chen C, Zheng Y, et al. A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death. J Biol Chem 2005;280: 41940-41952 (Pubitemid 43023163)
12. 12. Freedman RS, Pihl E, Kusyk C, Gallager HS, Rutledge F. Characterization of an ovarian carcinoma cell line. Cancer 1978;42:2352-2359 (Pubitemid 9125894)
13. 13. Behrens BC, Hamilton TC, Masuda H, et al. Characterization of cisdiamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 1987;47:414-418 (Pubitemid 17009602)
14. Lau DH, Lewis AD, Ehsan MN, Sikic BI. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res 1991;51: 5181-5187
15. 15. Liabakk NB, Sundan A, Torp S, Au krust P, Froland SS, Espevik T. Development, characterization and use of monoclonal antibodies against sTRAIL: measurement of sTRAIL by ELISA. J Immunol Methods 2002;259:119-128 (Pubitemid 33124390)
16. Dokun AO, Chu DT, Yang L, Bendelac AS, Yokoyama WM. Analysis of in situ NK cell responses during viral infection. J Immunol 2001 ; 167:5286-5293
17. Esumi H, Lu J, Kurashima Y, Hanaoka T. Antitumor activity of pyrvinium pamoate, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1Hpyrrol-3-yl)ethenyl]-1- methyl-qu inolinium pamoate salt, showing preferential cytotoxicity during glucose starvation. Cancer Sci 2004;95:685-690
18. Zebedin E, Simma O, Schuster C, et al. Leukemic challenge unmasks a requirement for PI3Kδ in NK cell-mediated tumor surveillance. Blood 2008;112:4655-4664
19. 19. Horak P, Pils D, Haller G, et al. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res 2005;3:335-343 (Pubitemid 40905625)
20. 20. Brown R, Clugston C, Burns P, et al. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 1993;55: 678-684 (Pubitemid 23328959)
21. Concin N, Stimpfl M, Zeillinger C, et al. Role of p53 in G2/M cell cycle arrest and apoptosis in response to γ-lrradiation in ovarian carcinoma cell lines. Int J Oncol 2003;22:51-57
22. Santoso JT, Tang DC, Lane SB, et al. AdenovIrus-based p53 gene therapy in ovarian cancer. Gynecol Oncol 1995;59:171-178
23. Wu GS, Burns TF, McDonald ER III, et al. KILLER/DR5 is a DNA damage-Inducible p53-regulated death receptor gene. Nat Genet 1997;17:141-143
24. 24. Koivusalo R, Krausz E, Ruotsalainen P, Helenius H, Hietanen S. Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand. Cancer Res 2002;62: 7364-7371 (Pubitemid 36025260)
25. 25. Inohara N, KosekI T, Hu Y, Chen S, Nunez G. CLARP, a death effector domain-containing protein interacts with caspase-8 and regulates apoptosis. Proc Natl Acad SCi U S A 1997;94:10717-10722 (Pubitemid 27430800)
26. 26. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388:190-195 (Pubitemid 27297457)
27. 27. Fukazawa T, Fujiwara T, Uno F, et al. Accelerated degradation of cellular FLIP protein through the ubIquItIn-proteasome pathway in p53-mediated apoptosis of human cancer cells. Oncogene 2001; 20:5225-5231 (Pubitemid 32844053)
28. 28. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that Induces apoptosis. Immunity 1995;3:673-682 (Pubitemid 26091143)
29. 29. Takeda K, Smyth MJ, Cretney E, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in Immune surveillance against tumor development. J Exp Med 2002;195:161-169 (Pubitemid 34461260)
30. 30. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002;2:850-861 (Pubitemid 37328903)
31. 31. Takeda K, Smyth MJ, Cretney E, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-γ-dependent suppression of subcutaneous tumor growth. Cell Immunol 2001;214:194-200. (Pubitemid 34499473)
32. Kelley RF, Totpal K, Lindstrom SH, et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 2005; 280:2205-2212
33. Muhlenbeck F, Schneider P, Bodmer JL, et al. The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. J Biol Chem 2000;275:32208-32213
34. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-162
35. 35. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-163 (Pubitemid 29068521)
36. 36. Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors. Cell Res 2004;14:359-372 (Pubitemid 43231798)
37. 37. Screaton GR, Mongkolsapaya J, Xu XN, Cowper AE, McMichael AJ, Bell JI. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol 1997;7:693-696 (Pubitemid 27408868)
38. Estes JM, Oliver PG, Straughn JM, Jr., et al. Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecol Oncol 2007;105:291-298
39. Hotte SJ, Hirte HW, Chen EX, et al. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 2008;14:3450-3455
40. 40. Tomek S, Horak P, Pribill I, et al. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. Gynecol Oncol 2004;94:107-114 (Pubitemid 38950505)
41. Duiker EW, de Vries EG, Mahalingam D, et al. Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. Clin Cancer Res 2009;15:2048-2057
42. 42. Kayagaki N, Yamaguchi N, Nakayama M, et al. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J Immunol 1999;163:1906-1913 (Pubitemid 29382191)
43. Takeda K, Hayakawa Y, Smyth MJ, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001;7:94-100.